Cantor Fitzgerald Predicts GH Research FY2026 Earnings

GH Research PLC (NASDAQ:GHRS - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for GH Research in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings of ($1.72) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $25.00 price target on the stock. The consensus estimate for GH Research's current full-year earnings is ($0.80) per share.

GHRS has been the topic of several other reports. Wall Street Zen lowered shares of GH Research from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Royal Bank of Canada began coverage on shares of GH Research in a report on Friday, March 7th. They issued an "outperform" rating and a $31.00 target price on the stock. Stifel Nicolaus increased their target price on shares of GH Research from $18.00 to $32.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. Guggenheim dropped their price target on GH Research from $32.00 to $29.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of GH Research in a research note on Friday, May 9th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $32.00.

GH Research Trading Down 6.3%

GHRS stock traded down $0.86 during trading on Tuesday, hitting $12.84. 133,821 shares of the company's stock were exchanged, compared to its average volume of 184,902. The stock has a market capitalization of $668.04 million, a price-to-earnings ratio of -16.25 and a beta of 0.97. GH Research has a 52-week low of $6.00 and a 52-week high of $20.50. The business has a 50-day moving average price of $10.45 and a two-hundred day moving average price of $10.29.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.42.

Institutional Trading of GH Research

Several hedge funds have recently modified their holdings of GHRS. BNP Paribas Financial Markets purchased a new position in GH Research in the fourth quarter worth $44,000. Palumbo Wealth Management LLC acquired a new position in shares of GH Research during the 1st quarter worth $142,000. XTX Topco Ltd purchased a new position in shares of GH Research in the 1st quarter valued at about $169,000. Two Sigma Investments LP acquired a new stake in shares of GH Research in the fourth quarter valued at about $117,000. Finally, Millennium Management LLC acquired a new stake in shares of GH Research in the fourth quarter valued at about $145,000. 56.90% of the stock is owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).